Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, single-center, single-dose, randomized, open-label, three-way crossover, pharmacokinetic study of AP-THC (tetrahydrocannabinol)

Trial Profile

A Phase I, single-center, single-dose, randomized, open-label, three-way crossover, pharmacokinetic study of AP-THC (tetrahydrocannabinol)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs Tetrahydrocannabinol (Primary)
  • Indications Fibromyalgia; Pain
  • Focus Pharmacokinetics
  • Most Recent Events

    • 10 Jan 2019 According to a Intec Pharma media release, first patient has been dosed in this trial.
    • 10 Jan 2019 Status changed from planning to recruiting, according to a Intec Pharma media release.
    • 19 Dec 2018 According to a Intec Pharma media release, the company plans to begin this trial in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top